Natoli JL, Manack A, Dean B, et al. Global prevalence of chronic migraine: a systematic review. Cephalalgia. 2010;30(5):599–609. https://doi.org/10.1111/j.1468-2982.2009.01941.x.
Schwedt TJ. Chronic migraine. BMJ. 2014. https://doi.org/10.1136/bmj.g1416(Epub ahead of print).
Silva A, Tepper SJ. Acute treatment of migraines. CNS Drugs. 2012;26:823–39.
Goadsby PJ, Wietecha LA, Dennehy EB, et al. Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. Brain. 2019;142:1894–904.
Lipton RB, Dodick DW, Ailani J, et al. Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: the ACHIEVE II randomized clinical trial. JAMA. 2019;322:1887–988.
Croop R, Goadsby PJ, Stock DA, et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet. 2019;394:737–45.
De Felice M, Ossipov MH, Porreca F. Update on medication-overuse headache. Curr Pain Headache Rep. 2011;15:79–83.
Meng ID, Dodick D, Ossipov MH, et al. Pathophysiology of medication overuse headache: insights and hypotheses from preclinical studies. Cephalalgia. 2011;31:851–60.
Barloese M, Petersen A, Stude P, et al. Sphenopalatine ganglion stimulation for cluster headache, results from a large, open-label European registry. J Headache Pain. 2018;19:6.
Tao H, Wang T, Dong X, et al. Effectiveness of transcutaneous electrical nerve stimulation for the treatment of migraine: a meta-analysis of randomized controlled trials. J Headache Pain. 2018;19:42.
Martelletti P, Jensen RH, Antal A, et al. Neuromodulation of chronic headaches: position statement from the European Headache Federation. J Headache Pain. 2013;14:86.
Cortese F, Pierelli F, Bove I, et al. Anodal transcranial direct current stimulation over the left temporal pole restores normal visual evoked potential habituation in interictal migraineurs. J Headache Pain. 2017;18:70.
Russo A, Tessitore A, Conte F, et al. Transcutaneous supraorbital neurostimulation in “de novo” patients with migraine without aura: the first Italian experience. J Headache Pain. 2015;16:69.
Miller S, Matharu M. Non-invasive neuromodulation in primary headaches. Curr Pain Headache Rep. 2017;21:14.
Magis D. Neuromodulation in migraine: state of the art and perspectives. Expert Rev Med Devices. 2015;12:329–39.
Yarnitsky D, Volokh L, Ironi A, et al. Nonpainful remote electrical stimulation alleviates episodic migraine pain. Neurology. 2017;88:1250–5.
Yarnitsky D, Dodick DW, Grosberg BM, et al. Remote electrical neuromodulation (REN) relieves acute migraine: a randomized, double-blind, placebo-controlled, multicenter trial. Headache J Head Face Pain. 2019;59:1240–52.
Rapoport AM, Bonner JH, Lin T, et al. Remote electrical neuromodulation (REN) in the acute treatment of migraine: a comparison with usual care and acute migraine medications. J Headache Pain. 2019;20:83.
Rapoport AM, Lin T. Device profile of the NerivioTM for acute migraine treatment: overview of its efficacy and safety. Expert Rev Med Devices. 2019;0:1–7.
Marmura MJ, Lin T, Harris D, et al. Incorporating remote electrical neuromodulation (REN) into usual care reduces acute migraine medication use: an open-label extension study. Front Neurol. 2020. https://doi.org/10.3389/fneur.2020.00226(Epub ahead of print).
Nir RR, Yarnitsky D. Conditioned pain modulation. Curr Opin Support Palliat Care. 2015;9:131–7.
Diener H-C, Tassorelli C, Dodick DW, et al. Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: fourth edition. Cephalalgia. 2019;39:687–710.
Lipton RB, Dodick DW, Silberstein SD, et al. Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: a randomised, double-blind, parallel-group, sham-controlled trial. Lancet Neurol. 2010;9:373–80.
Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the American Headache Society evidence assessment of migraine pharmacotherapies. Headache J Head Face Pain. 2015;55:3–20.
Lipton RB, Hamelsky SW, Dayno JM. What do patients with migraine want from acute migraine treatment? Headache J Head Face Pain. 2002;42:3–9.
Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders. Cephalalgia. 2018;38:1–211.
Smitherman TA, Burch R, Sheikh H, et al. The prevalence, impact, and treatment of migraine and severe headaches in the United States: a review of statistics from national surveillance studies. Headache J Head Face Pain. 2013;53:427–36.
Lipton RB, Stewart WF. Acute migraine therapy: do doctors understand what patients with migraine want from therapy? Headache J Head Face Pain. 1999;39:S20–S2626.
Ossipov MH, Dussor GO, Porreca F. Central modulation of pain. J Clin Investig. 2010;120:3779–877.
Schuh-Hofer S, Fischer J, Unterberg A, Treede RD, Ahmadi R. Spinal cord stimulation modulates descending pain inhibition and temporal summation of pricking pain in patients with neuropathic pain. Acta Neurochir. 2018;160(12):2509–19. https://doi.org/10.1007/s00701-018-3669-7.
Yarnitsky D, Arendt-Nielsen L, Bouhassira D, et al. Recommendations on terminology and practice of psychophysical DNIC testing. Eur J Pain. 2010;14:339–339.
Le Bars D, Dickenson AH, Besson J-M. Diffuse noxious inhibitory controls (DNIC). I. Effects on dorsal horn convergent neurones in the rat. Pain. 1979;6:283–304.
Lautenbacher S, Roscher S, Strian F. Inhibitory effects do not depend on the subjective experience of pain during heterotopic noxious conditioning stimulation (HNCS): a contribution to the psychophysics of pain inhibition. Eur J Pain. 2002;6:365–74.
Le Bars D, Dickenson AH, Besson J. Diffuse noxious inhibitory controls (DNIC). II. Lack of effect on non-convergent neurones, supraspinal involvement and theoretical implications. Pain. 1979;6:305.
Bouhassira D, Villanueva L, Bing Z, et al. Involvement of the subnucleus reticularis dorsalis in diffuse noxious inhibitory controls in the rat. Brain Res. 1992;595:353–7.
Millan MJ. Descending control of pain. Prog Neurobiol. 2002;66:355–474.
Lipton RB, Bigal ME, Stewart WF. Clinical trials of acute treatments for migraine including multiple attack studies of pain, disability, and health-related quality of life. Neurology. 2005;65:S50–58.
Dahlof CGH, Lipton RB, McCarroll KA, et al. Within-patient consistency of response of rizatriptan for treating migraine. Neurology. 2000;55:1511–6.
Lipton R, Dodick D, Adelman J, et al. Consistency of response to sumatriptan/naproxen sodium in a placebo-controlled, crossover study. Cephalalgia. 2009;29:826–36.
Dodick DW, Lipton RB, Ailani J, et al. Ubrogepant, an acute treatment for migraine, improved patient-reported functional disability and satisfaction in 2 single-attack phase 3 randomized trials, ACHIEVE I and II. Headache J Head Face Pain. 2020;60:686–700.
Lipton RB, Croop R, Stock EG, et al. Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine. N Engl J Med. 2019;381:142–9.
Blumenfeld AM, Varon SF, Wilcox TK, et al. Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS). Cephalalgia. 2011;31:301–15.
Silberstein SD, Lee L, Gandhi K, et al. Health care resource utilization and migraine disability along the migraine continuum among patients treated for migraine. Headache J Head Face Pain. 2018;58:1579–92.
Lipton RB, Chu MK. Conceptualizing the relationship between chronic migraine and episodic migraine. Expert Rev Neurother. 2009;9:1451–4.
Lipton RB, Hutchinson S, Ailani J, et al. Discontinuation of acute prescription medication for migraine: results from the chronic migraine epidemiology and outcomes (CaMEO) study. Headache J Head Face Pain. 2019;59:1762–72.
Barbanti P, Grazzi L, Egeo G, et al. Non-invasive vagus nerve stimulation for acute treatment of high-frequency and chronic migraine: an open-label study. J Headache Pain. 2015;16:61.
Thorlund K, Toor K, Wu P, et al. Comparative tolerability of treatments for acute migraine: a network meta-analysis. Cephalalgia. 2017;37:965–78.
Magis D, Sava S, d’Elia TS, et al. Safety and patients’ satisfaction of transcutaneous supraorbital neurostimulation (tSNS) with the Cefaly® device in headache treatment: a survey of 2,313 headache sufferers in the general population. J Headache Pain. 2013;14:95.